Roche has received CE mark approval for its Elecsys Neurofilament Light Chain (NfL) test, a new diagnostic tool designed to monitor neuroinflammation in patients with Relapsing-Remitting Multiple Sclerosis. The approval represents a significant advancement in the management of multiple sclerosis by enabling a minimally invasive, blood-based approach to tracking disease activity.

The Elecsys NfL test measures levels of neurofilament light chain, a protein released into the bloodstream when nerve cells are damaged. By quantifying this biomarker, the test provides valuable insights into neuroaxonal injury and inflammation, complementing traditional diagnostic methods such as MRI scans and clinical assessments.

Multiple sclerosis affects millions of people globally and requires consistent monitoring to manage disease progression effectively. However, access to routine imaging tests can be limited due to logistical and cost-related challenges. The introduction of a simple blood test offers a more accessible alternative, allowing for more frequent and convenient monitoring of patients.

The test is compatible with Roche’s widely used cobas diagnostic platforms, ensuring standardised and reliable results across different healthcare settings. Its ease of use and local sample collection capabilities can help reduce the burden on patients by minimising the need for travel to specialised centres.

With prior recognition under the US FDA’s Breakthrough Device Designation, the CE mark approval is expected to facilitate broader adoption of the test across regions that recognise the certification. This could significantly enhance early detection of disease activity changes and enable more timely clinical interventions.

Roche continues to expand its neurology portfolio, focusing on developing advanced diagnostic tools and therapies for complex neurological conditions. The Elecsys NfL test is part of the company’s broader effort to improve outcomes for patients through innovative, accessible, and data-driven healthcare solutions.